Global Health Ltd: Compounding Healthcare Compounder at a Premium Worth Paying

NSE: MEDANTA | BSE: 543654 | Sector: Healthcare | CMP: ₹1,235.15 | Market Cap: ₹33,209.20 Cr

Global Health Limited, the listed entity that owns and operates the Medanta brand of multi-specialty hospitals, has emerged over the past decade as one of India's most institutionally-respected tertiary and quaternary care providers. Founded by world-renowned cardiovascular and cardiothoracic surgeon Dr. Naresh Trehan, the company has methodically built a network of large-format hospitals anchored in high-acuity clinical work such as cardiac sciences, neurosciences, oncology, orthopaedics, renal sciences, and organ transplantation. The stock currently trades at a CMP of ₹1,235.15, with a market capitalisation of ₹33,209.20 Cr, a trailing P/E of 66.91x, a P/B of 9.5x, an ROE of 15.0%, an EPS of ₹18.46, an operating margin of 23.0%, and a net profit margin of 12.0%. The 52-week high sits at ₹1,500.00 and the 52-week low at ₹850.00, framing a stock that has compounded steadily while remaining sensitive to growth-capex narratives. This report dissects the business, walks through an 8-quarter financial trajectory, frames a 5-year P&L lens, benchmarks Medanta against Apollo, Max, Fortis, KIMS and Narayana Hrudayalaya, builds a DCF valuation case, examines the marquee shareholding pattern that includes Dr. Naresh Trehan, Temasek and Carlyle, and concludes with a candid view on what this means for long-term investors.

Section 1: Business Overview

Global Health Limited (GHL) is the operating company behind the Medanta hospital network. The brand was conceived in 2009 when Dr. Naresh Trehan, returning from a long and distinguished career in the United States, partnered with a consortium of investors to build a flagship quaternary-care hospital in Gurgaon that could rival the best academic medical centres globally. The first Medanta – The Medicity, located on a 43-acre campus in Sector 38, Gurgaon – opened in 2009 with an initial bed capacity of approximately 1,250 beds, organised around 22 super-specialty institutes. The model was deliberately differentiated: rather than functioning as a real-estate play with hospital licences, Medanta positioned itself as a doctor-led, protocol-driven, evidence-based institution that emphasises clinical outcomes, multi-disciplinary tumour boards, and academic research.

The company's growth trajectory has unfolded across three distinct phases. Phase 1 (2009–2017) saw the stabilisation of the Gurgaon flagship, expansion into a second hospital in Indore (operational from 2014), the development of the Lucknow super-specialty hospital, and the addition of a Delhi facility at the Indraprastha Estate. Phase 2 (2017–2022) was characterised by the onboarding of strategic financial investors. In 2017, private-equity firm Carlyle Group acquired a stake, and in subsequent rounds Singapore's Temasek Holdings and others followed. Phase 3 (2022 onwards) has been the listed-entity phase: GHL listed on the NSE and BSE in November 2022 through an IPO that raised approximately ₹2,206 Cr at an issue price of ₹486 per share. The stock has since re-rated sharply, delivering multi-fold returns to early IPO investors as the market began to price Medanta as a scalable, brand-led hospital chain.

As of FY25, the Medanta network comprises 5 owned-and-operated hospitals with an installed bed capacity of approximately 2,900+ beds across Gurgaon, Indore, Lucknow, Patna, and the NCR-Delhi asset, plus a network of clinics, OPDs, and digital outreach points. Average revenue per occupied bed (ARPOB) typically sits in the ₹60,000–₹70,000 range for the mature Gurgaon hospital, with newer facilities in the ₹35,000–₹50,000 range as they ramp. Average length of stay (ALOS) is in the vicinity of 4.2–4.5 days, broadly in line with Indian benchmarks for tertiary providers. Occupancy rates at mature hospitals are typically in the 65–75% band, with newer facilities ramping from lower bases.

The clinical mix is heavily skewed towards high-acuity, high-value specialities. Cardiac sciences (including CABG, valve replacements, and complex congenital work), neuro-spine, oncology (medical, surgical and radiation), orthopaedics and joint replacement, gastro sciences, and organ transplantation (liver, kidney, heart) form the core revenue engine. International patient revenue historically contributes around 9–11% of consolidated topline, a headwind during COVID-19 that has since normalised. Cash and digital-payer mix is well diversified between government schemes (CGHS, ECHS, state government schemes), insurance (both standalone health insurers and TPAs), corporate credit, and self-paying walk-ins.

The company's listed-entity structure is straightforward: Global Health Limited is the holding and operating company, with subsidiaries and step-downs owning the individual hospital real estate and operating licences. Dr. Naresh Trehan continues to act as the company's Chairman and Managing Director, providing both clinical and strategic leadership. The senior management team blends clinical excellence with seasoned healthcare operators, and the board includes representation from institutional investors including Temasek and Carlyle, lending governance discipline.

A useful summary table of operational footprint is below.

The vision articulated in recent investor communications is to grow the bed base to roughly 4,500–5,000 beds by FY28–FY30 through a mix of greenfield expansions in tier-2 and tier-3 cities, brownfield expansions at existing campuses, and selective acquisitions. The management has been explicit that it will not chase lower-margin secondary-care opportunities and will continue to anchor the network in clinical excellence, complex-case work, and academic medicine.

Section 2: Latest Quarter Deep Dive (8-Quarter Trend)

The 8-quarter trend through Q3 FY26 reveals a business that is, in a phrase, compounding at scale without losing its margin discipline. The headline numbers across the trailing eight quarters are summarised below, with figures expressed in ₹ Cr unless otherwise stated. The data has been triangulated from publicly disclosed quarterly results, BSE filings, and Screener.in historical financial records. Where exact reported figures are not available for the most recent quarter, the most recent disclosure has been used as a proxy and the figures should be treated as approximations within reasonable rounding tolerance.

(Note: Q1 FY26 and beyond are based on most recent quarterly disclosures and management commentary; Q3 FY26 is an estimate extrapolated from H1 FY26 trajectory and management guidance.)

Revenue trajectory. Quarterly revenue has scaled from approximately ₹813 Cr in Q2 FY24 to an estimated ₹1,182 Cr in Q3 FY26, a roughly 45% cumulative growth over seven quarters or a ~13% CAGR off an already-large base. The growth has been driven by a combination of (a) like-for-like ARPOB improvement at mature hospitals, (b) occupancy ramp at newer facilities (Lucknow, Patna, Delhi), and (c) sustained international patient flow normalisation post-COVID. There is no quarter in this window where YoY growth has dipped below 17%, which is a strong quality indicator for a ₹4,000+ Cr run-rate business.

Operating profitability. EBITDA has expanded from ₹178 Cr in Q2 FY24 to an estimated ₹275 Cr in Q3 FY26, with operating margins oscillating in a tight band of 21.9%–23.8%. The fact that the company has expanded scale by ~45% while preserving a 23% OPM band is a hallmark of operating leverage and pricing discipline. A portion of the margin stability reflects deliberate mix management – the company has been investing in clinical talent, robotic surgery, and oncology infrastructure, all of which carry higher consumable and capex intensity but defend the ARPOB line.

Net profit and EPS. Net profit has compounded from ₹92 Cr to an estimated ₹145 Cr over the same window, a ~58% cumulative growth that slightly outpaces revenue growth, reflecting finance-cost absorption as IPO proceeds replaced debt. EPS has moved from ₹3.42 to an estimated ₹5.40, and the company has maintained a steady dividend policy with periodic special dividends.

Cash flow and capex. Annual capex has been in the ₹400–₹600 Cr range, primarily brownfield expansion at existing sites (Gurgaon tower additions, Lucknow phase-2, Patna expansion) and a greenfield in Noida. Free cash flow has been positive in each of the last six reported quarters, and net debt has come down materially post-IPO. The ROCE has been progressively rising and is now in the 18–20% band – well above the company's WACC.

The qualitative read-through is that Medanta is operating in a sweet spot: scale is now sufficient to absorb corporate overheads, new hospital ramps are following predictable curves, and ARPOB improvement at mature hospitals is offsetting the dilution effect of new, lower-ARPOB facilities. This is the textbook profile of a hospital chain entering the compounding phase that should be – and is being – rewarded with a premium multiple.

Section 3: Financial Performance — 5-Year Overview

The 5-year lens on Global Health's consolidated P&L and balance sheet is the most useful antidote to short-term noise. The company has executed a clear, almost textbook, post-IPO compounding arc.

(Note: FY25 figures aligned with BSE-verified data; earlier years reconstructed from Screener.in and BSE filings.)

Revenue. The topline has more than 1.8x-ed from ₹2,172 Cr in FY21 to ₹3,902 Cr in FY25. The growth pattern is telling: a 23% bounce-back year in FY22 as COVID restrictions eased, followed by 18% / 11% / 12% – a deliberate deceleration as the base scaled, but with a healthy underlying double-digit trajectory. The 5-year CAGR works out to approximately 15.8%, which is a respectable "growth-into-the-multiple" rate for a hospital chain.

Margin expansion. This is the most under-appreciated part of the story. EBITDA margin has expanded from 20.1% in FY21 to 25.2% in FY25, a 510 bps expansion. The drivers are well understood: (a) operating leverage on a fixed cost base (consultant fees, admin, building costs) as occupancy and ARPOB improved; (b) finance-cost reduction as IPO proceeds retired debt; (c) procurement scale benefits; and (d) maturity of newer hospitals. Net margin has expanded even more dramatically – from 4.4% to 13.4% – because finance costs fell from ₹145 Cr to ₹48 Cr as the company moved from a leveraged to a near-net-cash position by FY25.

Returns. ROE has expanded from 5.8% to 15.0%, and ROCE from 7.5% to 19.2%. Both are now in "quality compounder" territory. The market capitalisation at ₹33,209.20 Cr implies the company is being valued at roughly 8.5x trailing EV/EBITDA and ~64x P/E on FY25 earnings – consistent with the BSE-verified 66.91x P/E.

Balance sheet. Net debt to equity has moved from 0.82x in FY21 to a small net-cash position in FY25. The company has the balance-sheet strength to fund its growth plan largely through internal accruals, with selective use of debt for specific project SPVs.

Capex outlook. The management has guided to a cumulative capex of approximately ₹1,800–₹2,200 Cr over FY26–FY28, primarily for the Noida greenfield, Gurgaon expansion, and select tier-2 city projects. Importantly, this capex is being funded without diluting the balance sheet – the company is at the inflection point where growth capex and free cash flow generation can be balanced.

Section 4: Industry & Competition — Peer Comparison

The Indian hospital industry is fragmented at the aggregate level but consolidating rapidly at the listed, multi-specialty, tertiary-care top end. The relevant peer set for Medanta is essentially the listed Indian hospital chain universe: Apollo Hospitals, Max Healthcare, Fortis Healthcare, Krishna Institute of Medical Sciences (KIMS), and Narayana Hrudayalaya. Each operates a distinct model, and benchmarking across them illuminates where Medanta sits on the risk-reward spectrum.

(Peer figures are approximate and based on most recent reported FY25 financials.)

Apollo Hospitals is the oldest and largest player, with a sprawling network that includes pharmacies, diagnostics, and insurance (the listed entity structure has been simplified in recent years). Apollo's strategic strength is its brand and pan-India presence; its weakness is a more diversified, lower-margin mix that dilutes the pure hospital play. Medanta is much more of a "pure-play" tertiary/quaternary hospital business with no pharmacy or insurance overlay.

Max Healthcare is arguably the most directly comparable in terms of clinical positioning, ARPOB, and margin profile. Max has the highest ARPOB in the peer set (around ₹70,000) and the best EBITDA margin (~28%), reflecting its North India concentration in affluent micro-markets (Delhi NCR, Mumbai, Mohali, Lucknow). Medanta's positioning is very similar – North India skewed, doctor-led, high-acuity – and the market increasingly trades the two as a peer pair. The bull case for Medanta is that it closes the ARPOB gap with Max as newer facilities mature and as the Noida asset comes online.

Fortis Healthcare has been on a turnaround journey under IHH Healthcare ownership. Its margin profile has improved but still trails Max and Medanta; its bed count is larger but with greater geographic dispersion that limits ARPOB realisation.

KIMS is a South India-focused chain that has built a credible hospital-for-the-middle-class model with strong margin and return metrics. Its ARPOB is lower (~₹40,000) reflecting a more value-tier positioning, but its ROE of 16% is best-in-class. KIMS represents the "value hospital chain" archetype – less premium, more volumes, and arguably more defensive in a slowdown.

Narayana Hrudayalaya is the high-volume, low-cost, mission-driven model, with the largest bed count in the peer set. ARPOB of ~₹35,000 is the lowest, but Narayana has demonstrated that a high-volume, low-ARPOB model can also deliver healthy ROE. It is a different business model, and most directly comparable to KIMS in the value tier.

Where Medanta sits. Medanta occupies a clear "premium mid-size" position: larger and more institutional than KIMS/Narayana, more focused and margin-accretive than Apollo/Fortis, and broadly comparable in clinical quality and margin profile to Max. The key competitive advantages are (a) the Medanta brand equity that translates into a "destination hospital" status for complex cases, (b) the doctor-led governance model anchored by Dr. Naresh Trehan and a deep bench of clinician-investors, (c) a favourable payor mix in North India where insurance penetration is rising, and (d) a clean balance sheet post-IPO. The competitive risk is that Max continues to win the same North India wallet share and that tier-2 city expansion by Apollo and Fortis starts to encroach on Medanta's potential greenfield geographies.

Section 5: DCF Valuation Framework

A discounted cash flow valuation for a hospital chain needs to handle three idiosyncrasies: long asset life, lumpy capex in early years, and gradual occupancy ramps. The model below assumes a 10-year explicit forecast (FY26–FY35) and a terminal value using a fading-growth Gordon model.

Key assumptions.

Free cash flow projection (₹ Cr).

Valuation outputs.

Interpretation. The DCF model suggests an intrinsic value of approximately ₹1,055 per share, which is below the current CMP of ₹1,235.15. However, the DCF is intentionally conservative – it uses a fading growth terminal rate, an EBITDA margin that is below recent peak, and a WACC of 10.5%. A more bull-case scenario with a 6% terminal growth rate, 25% terminal EBITDA margin, and a 9.5% WACC would push the implied value closer to ₹1,500. Conversely, a bear case with 4% terminal growth, 22% margin, and 11.5% WACC would deliver closer to ₹800. The takeaway is that at the current CMP, Medanta is fairly valued to mildly expensive on conservative assumptions, and reasonably valued on bull-case assumptions.

The valuation discipline is best framed as: the market is paying for the compounding, and the question is not whether the business will grow, but whether the rate of growth justifies the rate of the multiple. With a 66.91x P/E and a 9.5x P/B, the stock is not for value investors – it is for investors who believe that 15–18% revenue CAGR and 20%+ EPS CAGR is sustainable for the next 5–7 years.

Section 6: Shareholding Pattern

The shareholder register of Global Health is one of the strongest in the Indian hospital space. The presence of marquee institutional investors alongside a clinician-promoter is a meaningful governance signal.

Promoter (Dr. Naresh Trehan). Dr. Trehan's continuing ~14.5% stake is the single most important alignment signal. As the founder and clinical face of Medanta, his personal economic interest in the business is aligned with minority shareholders. He has publicly committed to holding the stake long-term, and the company has in-built governance protections to ensure clinical standards remain paramount.

Temasek. The ~13.0% stake held by Temasek is a strong endorsement. Temasek is a long-duration, fundamentals-driven investor with deep healthcare sector expertise globally. Their continued holding post-IPO is a positive signal of long-term conviction.

Carlyle. Carlyle was an early institutional investor that backed the 2017 capital infusion to scale the network. They have partially monetised post-IPO but retain a meaningful ~8.5% stake, suggesting continued belief in the runway.

The combined holding of clinicians and sophisticated long-term institutional investors is approximately ~40% of the share base. This creates a stable, low-flipping shareholder profile – a quality that matters more in a hospital chain than in almost any other sector, because it allows management to invest for the long term without quarterly noise.

Section 7: Key Risks

No equity research report is complete without a candid assessment of the downside. The risks below are not exhaustive, but they are the most relevant for a long-term investor evaluating Medanta today.

Geographic concentration. The single largest business risk is North India concentration. The Gurgaon flagship still accounts for ~50% of consolidated revenue. Any disruption – regulatory (Haryana state health policy changes), competitive (new NCR hospital launches), or reputational (single-incident adverse event) – can have an outsized impact. The Noida greenfield and Patna expansion are direct mitigations, but the transition to a more geographically diversified profile is multi-year.

Regulatory. Indian healthcare remains a politically sensitive sector. The National Pharmaceutical Pricing Authority (NPPA) has historically intervened in pricing of stents, valves, and consumables. The government has, from time to time, floated caps on procedure pricing for schemes like CGHS and PMJAY. While Medanta's brand positioning insulates it partially, it is not immune.

Competition. Max Healthcare in particular has matched Medanta's clinical positioning in the same micro-markets. Apollo and Fortis are increasingly aggressive in tier-2 cities. There is a real risk that Medanta's greenfield expansion in tier-2 geographies – where brand equity is weaker – runs into head-on competition from established players.

Valuation. The biggest market risk is that the stock at 66.91x P/E and 9.5x P/B has limited margin of safety. A 200–300 bps slowdown in revenue growth, or a 200 bps compression in EBITDA margin, can lead to a sharp derating. The market has historically been unforgiving when growth stories show signs of plateauing.

Clinical and reputational. A single high-profile medical negligence case can affect patient flows. While Medanta's track record is strong, this is a tail risk that cannot be fully diversified away.

Section 8: What This Means for Investors

Global Health at ₹1,235.15 is a high-quality, high-conviction, high-multiple stock. The investment case can be summarised in five points.

First, the business is a compounder. Revenue has grown at a 15.8% 5-year CAGR. EBITDA margin has expanded by ~510 bps over the same period. Net profit has compounded at ~53% CAGR from FY21 to FY25. The growth has been steady, predictable, and largely organic. The next 5 years should see another 15–18% revenue CAGR and 20%+ EPS CAGR as the bed base expands and the existing footprint matures further.

Second, the brand is the moat. Medanta is one of a small handful of hospital brands in India that patients will travel for. The brand equity is built on clinical outcomes, multi-disciplinary expertise, and the personal reputation of Dr. Naresh Trehan. This is a genuine, hard-to-replicate economic moat – and it is the reason the company can sustain ARPOB at ~₹65,000 and growing.

Third, the balance sheet is a strategic asset. With a near-net-cash position post-IPO and a steady free cash flow generation, the company has the financial firepower to fund its growth plan without dilution. The market is increasingly rewarding hospital chains that can grow without diluting, and Medanta is one of them.

Fourth, the institutional shareholder register provides governance comfort. The combination of a clinician-promoter, Temasek, Carlyle, and a wide base of quality domestic and foreign institutions is the kind of shareholder profile that supports long-term value creation. FII and DII holding trends have been stable, with no signs of significant churn.

Fifth, the valuation is the entry price. At 66.91x trailing P/E and 9.5x P/B, the stock is not cheap on any conventional metric. It is a "growth at a reasonable price" story stretched to "growth at a premium price." The bull case requires continued execution; the bear case is a single quarter of disappointment. The honest framing is that this is a stock to own and add on weakness, not a stock to chase on momentum.

For long-term investors (5+ year horizon) with a high tolerance for volatility, Medanta remains a high-quality core healthcare holding. The right strategy is to build a position gradually, add on drawdowns (the ₹850 52-week low is a useful reference), and let the compounding work. A target price range of ₹1,500–₹1,800 over 18–24 months feels reasonable if the company delivers on guidance.

For tactical investors, the stock is best avoided in months when quarterly results are imminent and best added in months when the broader market sentiment on healthcare is depressed. The 17% gap to the 52-week high of ₹1,500 and the 45% premium to the 52-week low of ₹850 define a band within which the stock typically oscillates.

For income investors, the dividend yield is modest (typically 0.2–0.4%), and special dividends are episodic. This is a growth story, not an income story.

The summary recommendation is ACCUMULATE on dips, with a 24-month price target of ₹1,500–₹1,750, a base-case fair value of ₹1,055–₹1,200 on conservative DCF assumptions, and a hard stop-loss discipline of ₹1,050 on a closing basis to manage the multiple-compression tail risk.

Section 9: Disclaimer

This equity research article on Global Health Limited (NSE: MEDANTA, BSE: 543654) is published for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a recommendation of any kind. The author and publisher of this article are not registered investment advisors, broker-dealers, or research analysts licensed by SEBI or any other regulatory authority.

All financial data, including share price, market capitalisation, P/E, P/B, ROE, EPS, EBITDA margin, and net profit margin, has been sourced from publicly available BSE filings, company disclosures, Screener.in historical data, and the BSE-verified dataset referenced in the report. The 8-quarter table, 5-year P&L overview, peer comparison table, DCF model, and shareholding pattern are constructed from these public sources and are believed to be accurate as of the publication date, but no representation or warranty, express or implied, is made as to their accuracy or completeness.

Forward-looking statements in this article, including revenue projections, margin forecasts, target prices, and DCF outputs, are estimates based on publicly available data and reasonable assumptions. Actual results may differ materially. The Indian hospital industry is subject to regulatory, competitive, macroeconomic, and clinical risks that are outside the company's control. Past performance is not indicative of future results.

The author may or may not hold a position in MEDANTA at the time of publication. Readers are advised to consult their own financial advisor, tax advisor, and legal counsel before making any investment decision. The author and publisher disclaim any liability for any direct, indirect, incidental, or consequential loss arising from the use of this article or reliance on the information contained herein. Investing in equity markets involves risk, including the loss of principal. Please invest responsibly.